Therapeutic area intelligence for Neuropsychiatry with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 4
Companies: 4

Companies

AbbVie →

Bristol-Myers Squibb →

Johnson & Johnson →

Karuna Therapeutics →

Assets

Recent signals(1)

ClinicalJuly 13, 2026

Longitudinal Study on Puberty's Impact on Neuropsychiatric Disorders

A longitudinal study will investigate how puberty affects brain structure, function, and stress responsivity in boys and girls.

Upcoming catalysts(3)

Phase II Readout

AbbVie — Emraclidine

Second-wave muscarinic data will clarify class viability post-KarXT launch.

September 18, 2026 · Phase II

PDUFA Date

Johnson & Johnson — Caplyta

MDD approval would significantly expand Caplyta commercial footprint.

August 5, 2026 · NDA/BLA

Commercial Launch

Karuna Therapeutics — KarXT

First-in-class muscarinic agonist launch tests payer appetite for novel MOA in psychiatry.

June 18, 2026 · Commercial

Indications

Alzheimer's psychosis →

Developmental Disorders →

Major depressive disorder →

Schizophrenia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.